Combining Biology-based and MRI Data-driven Modeling to Predict Response to Neoadjuvant Chemotherapy in Patients with

Casey E Stowers1, Chengyue Wu1, Zhan Xu1

  • 1From the Oden Institute for Computational Engineering and Sciences, The University of Texas at Austin, Austin, Tex (C.E.S., C.W., J.I.T., T.E.Y.); Chandra Family Department of Electrical and Computer Engineering, The University of Texas at Austin, Austin, Tex (S.K., J.I.T.); Livestrong Cancer Institutes, The University of Texas at Austin, Austin, Tex (T.E.Y.); Departments of Imaging Physics (C.W., Z.X., J.B.S., J.M., T.E.Y.), Abdominal Imaging (G.M.R.), Breast Imaging (C.W., G.M.R.), Breast Medical Oncology (C.Y.), Biostatistics (C.W.), and Institute for Data Science in Oncology (C.W.), The University of Texas MD Anderson Cancer Center, Houston, Tex; and Departments of Biomedical Engineering (C.W., T.E.Y.), Diagnostic Medicine (J.I.T., T.E.Y.), and Oncology (T.E.Y.), The University of Texas at Austin, 107 W Dean Keeton St, Stop C0800, Austin, TX 78712.

PubMed
Summary

This study combined deep learning and a biology-based model to predict triple-negative breast cancer response to neoadjuvant chemotherapy (NAC) using MRI data. The integrated model accurately predicted tumor changes, aiding treatment decisions before therapy begins.

Related Concept Videos